Diabetogen Biosciences Inc.
This article was originally published in Start Up
Executive Summary
Diabetogen Biosciences' therapies target the autoimmune component of Type I diabetes and may help prevent onset of the disease.
You may also be interested in...
Teasing Out Next-Generation Diabetes Drugs
Many start-ups are developing diabetes drugs based on known targets which could attract Big Pharma partners and get to the clinic quickly, while a few invest in novel compounds that are either riskier or address the field's smaller subsets. Among the former are Phenomix, Plexxikon, CareX and Prosidion; among the latter are DiaKine, and DiaMedica. In all cases, these companies are looking to partner with Big Pharma, which is aggressively pursuing small-molecule drugs for diabetes.
Tackling Diabetes and Obesity
The growing incidence of these diseases, and their complexity, provide opportunities for a number of different approaches
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”